Valeritas (NASDAQ:VLRX) had its price objective hoisted by investment analysts at Oppenheimer from $1.25 to $12.00 in a research note issued on Tuesday, The Fly reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s price target indicates a potential upside of 282.17% from the stock’s current price. Oppenheimer also issued estimates for Valeritas’ Q2 2019 earnings at ($2.90) EPS, Q3 2019 earnings at ($2.66) EPS, Q4 2019 earnings at ($2.53) EPS, FY2019 earnings at ($11.14) EPS and FY2020 earnings at ($9.37) EPS.

Separately, ValuEngine cut Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd.

NASDAQ:VLRX traded down $0.61 on Tuesday, reaching $3.14. 35,197 shares of the company’s stock traded hands, compared to its average volume of 287,833. The company has a debt-to-equity ratio of 29.19, a quick ratio of 2.81 and a current ratio of 3.32. The stock’s 50-day moving average is $3.00. The stock has a market capitalization of $14.71 million, a price-to-earnings ratio of -0.09 and a beta of 1.79. Valeritas has a 12 month low of $2.10 and a 12 month high of $34.00.

Valeritas (NASDAQ:VLRX) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.15) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.15). The business had revenue of $6.40 million for the quarter, compared to analysts’ expectations of $6.20 million. Valeritas had a negative return on equity of 1,757.04% and a negative net margin of 183.53%. As a group, sell-side analysts expect that Valeritas will post -11.2 EPS for the current year.

In other Valeritas news, major shareholder Armistice Capital Master Fund purchased 226,000 shares of the firm’s stock in a transaction on Tuesday, May 21st. The shares were acquired at an average cost of $0.66 per share, with a total value of $149,160.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders have acquired 350,000 shares of company stock worth $234,640. Insiders own 1.02% of the company’s stock.

Institutional investors have recently modified their holdings of the company. CVI Holdings LLC purchased a new position in shares of Valeritas during the fourth quarter valued at about $832,000. Millennium Management LLC purchased a new position in shares of Valeritas during the fourth quarter valued at about $165,000. Northern Trust Corp grew its position in shares of Valeritas by 855.4% during the fourth quarter. Northern Trust Corp now owns 185,469 shares of the company’s stock valued at $60,000 after purchasing an additional 166,057 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Valeritas by 138.0% during the fourth quarter. Geode Capital Management LLC now owns 186,971 shares of the company’s stock valued at $60,000 after purchasing an additional 108,416 shares in the last quarter. Finally, Weiss Multi Strategy Advisers LLC purchased a new position in shares of Valeritas during the fourth quarter valued at about $41,000.

About Valeritas

Valeritas Holdings, Inc, a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization.

Featured Story: Cost of Debt

The Fly

Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with MarketBeat.com's FREE daily email newsletter.